UCB S.A.

Recent Events

News & Analysis

ucb s.a. - All News and Analysis

• UCB Receives Complete Response Letter From U.S. FDA for Use of Cimzia(R) in Rheumatoid Arthritis Patients

  - 2009-01-05

  Press release - regulated information - UCB announced today that the US Food and Drug Administration FDA has issued a Complete Response Letter CRL relating to the Biologics License Application BLA of Cimzia® certolizumab pegol, the first PEGylated anti-TNF, for the treatment of rheumatoid arthritis RA. As a prerequisite...

  Tags: FDA, UCB S.A.

• Cimzia(R) studies show significant clinical benefits for mono- and combination therapy in patients with rheumatoid arthritis

  - 2008-11-18

  * FAST 4WARD showed monotherapy Cimzia® 400 mg, dosed every four weeks, provided significant and effective clinical benefits compared to placebo * RAPID 2 trial showed Cimzia®, together with methotrexate MTX, achieved significant reduction in signs, symptoms and progression of rheumatoid...

  Tags: UCB S.A.

• Otsuka and UCB agreed to co-develop and co-promote Keppra(R) and Cimzia(R) in Japan

  - 2008-06-10

  * Otsuka and UCB have agreed to co-promote UCB's anti epileptic drug, Keppra® and its anti-TNF alpha drug, Cimzia® in Japan - the second largest pharmaceutical market in the world. Otsuka will also co-develop new indications. ...

  Tags: UCB S.A.

• Ucb Sells Otc Delsym To Adams Respiratory Therapeutics

  - 2006-07-01

  UCB S.A., Brussels, Belgium, has reached an agreement with Adams Respiratory Therapeutics Inc. (NASDAQ: ARxT) to sell Delsym dextromethorphan polistirex, an over-the-counter OTC 12-hour liquid cough suppressant. In addition, the two companies have entered into a separate agreement for the licensing of the 12-hour liquid technology. The financial terms...

  Tags: UCB S.A.

• UCB SELLS TO ADAMS RESPIRATORY THERAPEUTICS OTC DELSYM(R) 12-HOUR COUGH SUPPRESSANT LIQUIDS

  - 2006-05-25

  Brussels Belgium, 25 May 2006 - 8:00 am CET - UCB S.A. announces today that it has reached an agreement with Adams Respiratory Therapeutics Inc. (NASDAQ: ARxT) to sell Delsym® dextromethorphan polistirex, an over-the-counter OTC 12-hour liquid cough suppressant. In addition, the two companies have entered into a separate agreement...

  Tags: UCB S.A.

• Ucb Licenses Sepracor U.S. Patents For Antihistamine

  - 2006-04-01

  UCB S.A. (EURONEXT: UCB) and Sepracor Inc. (Nasdaq: SEPR) have signed a licensing agreement relating to the antihistamine levocetirizine. Under this agreement, Sepracor has exclusively licensed to UCB all of Sepracor's patents and patent applications in the United States regarding levocetirizine and royalties will be payable to Sepracor on U.S....

  Tags: Sepracor Inc., UCB S.A.

• Crucell and DSM Biologics Announce PER.C6(R) Licensing Agreement with UCB

  - 2006-03-14

  Leiden/Sittard, The Netherlands, March 14, 2006 - Dutch biotechnology company Crucell N.V. (Euronext and NASDAQ: CRXL; Swiss Exchange: SW CRX) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6® research license agreement with global biopharmaceutical leader...

  Tags: Company, Crucell N.V., DSM Biologics, UCB S.A.

• UCB Licenses Sepracor U.S. patents for antihistamine Levocetirizine

  - 2006-02-23

  BRUSSELS Belgium and MARLBOROUGH, Mass. USA, February 23, 2006 -- UCB S.A. (EURONEXT: UCB) and Sepracor Inc. (Nasdaq: SEPR) today announced a licensing agreement relating to the antihistamine levocetirizine. Under this agreement, Sepracor has exclusively licensed to UCB all of Sepracor's patents and patent applications in the United States regarding...

  Tags: Sepracor Inc., UCB S.A.

• Growing Demand From Epilepsy Patients for Seizure Response Dogs Answered by Partnership Between UCB Pharma, Inc. and Canine Assistants

  - 2005-11-01

  UCB Pharma, Inc., and Canine Assistants today announced a multi-year partnership to sponsor seizure response dogs for epilepsy patients across the U.S. These dogs represent the fastest growing requests received by Canine Assistants. Under the sponsorship, UCB will provide support for the care, training and lifetime veterinary costs...

  Tags: UCB S.A.

• The Belgians are coming; Celltech.(Celltech and its Belgian bidder)(UCB S.A.)

  - 2004-05-22

  Horror at a foreign bid for a British biotech outfit CELLTECH is Britain's number-two biotech company. In 1999 its sales were only [pounds sterling]44m, but reached [pounds sterling]353m last year, and due on the market in 2007 it has an anti-arthritis drug which, it...

  Tags: UCB S.A.